For example, in individuals with colorectal cancer, increased SLC2A3 expression was related with decreased overall survival and disease-free survival (Kim et al., 2019), while increased SLC16A5 expression predicted increased survival in prostate cancer patients (Meng et al., 2021). This evidence concerns the gene SLC2A3 and Familial prostate cancer.